Is EPZM or XYLD a better dividend investment in 2026?

EPZM currently yields 136.05% with a 5% 5-year dividend growth rate. XYLD yields 10.98% with 0.5% growth. The better choice depends on your goal: EPZM offers higher current income.

What is the dividend yield difference between EPZM and XYLD?

EPZM has a forward dividend yield of 136.05% ($2.00/share annually). XYLD yields 10.98% ($4.30/share annually). The yield gap is 125.07 percentage points.

Home › Compare › EPZM vs XYLD

EPZM vs XYLD: Dividend Comparison 2026

EPZM yields 136.05% · XYLD yields 10.98%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 EPZM wins by $15.37M in total portfolio value

INVESTMENT

TIME HORIZON10 years

EPZM

● Live price

136.05%

Share price

$1.47

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$15.39M

Annual income

$6,293,323.05

Full EPZM calculator →

XYLD

Global X S&P 500 Covered Call ETF

● Live price

10.98%

Share price

$39.13

Annual div

$4.30

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.3K

Annual income

$3,219.02

Full XYLD calculator →

Portfolio growth — EPZM vs XYLD

📍 EPZM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	EPZM	XYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, EPZM + XYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

EPZM pays

XYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EPZM

Annual income on $10K today (after 15% tax)

$11,564.63/yr

After 10yr DRIP, annual income (after tax)

$5,349,324.59/yr

XYLD

Annual income on $10K today (after 15% tax)

$933.63/yr

After 10yr DRIP, annual income (after tax)

$2,736.17/yr

At 15% tax rate, EPZM beats the other by $5,346,588.43/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EPZM + XYLD for your $10,000?

EPZM: 50%XYLD: 50%

100% XYLD50/50100% EPZM

Portfolio after 10yr

$7.71M

Annual income

$3,148,271.04/yr

Blended yield

40.84%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPZM right now

EPZM

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

XYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EPZM buys

XYLD buys

No recent congressional trades found for EPZM or XYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricEPZMXYLD

Forward yield	136.05% ✓	10.98%
Annual dividend / share	$2.00	$4.30 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$15.39M	$25.3K ✓
Annual income after 10y	$6,293,323.05 ✓	$3,219.02
Total dividends collected	$14.14M	$19.6K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: EPZM vs XYLD ($10,000, DRIP)

Year	EPZM Portfolio	EPZM Income/yr	XYLD Portfolio	XYLD Income/yr	Gap
1← crossover	$24,305	$13,605.44	$10,818	$1,098.39	+$13.5K → EPZM
2	$56,912	$30,905.26	$11,738	$1,222.51	+$45.2K → EPZM
3	$128,528	$67,631.59	$12,774	$1,364.64	+$115.8K → EPZM
4	$280,268	$142,743.86	$13,944	$1,527.86	+$266.3K → EPZM
5	$590,792	$290,905.24	$15,270	$1,715.87	+$575.5K → EPZM
6	$1,205,245	$573,097.64	$16,775	$1,933.09	+$1.19M → EPZM
7	$2,382,274	$1,092,661.12	$18,490	$2,184.87	+$2.36M → EPZM
8	$4,567,482	$2,018,449.47	$20,450	$2,477.63	+$4.55M → EPZM
9	$8,503,963	$3,616,756.90	$22,697	$2,819.19	+$8.48M → EPZM
10	$15,392,564	$6,293,323.05	$25,280	$3,219.02	+$15.37M → EPZM

EPZM vs XYLD: Complete Analysis 2026

EPZM — Stock

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..

Full EPZM Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →

📬

Get this EPZM vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EPZM vs SCHD EPZM vs JEPI EPZM vs O EPZM vs KO EPZM vs MAIN EPZM vs QYLD EPZM vs JEPQ EPZM vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.